A Pilot Study of Cisplatin, 5-Fluorouracil and High Dose Leucovorin in Chinese Patients with Head and Neck Cancer

增熙 林; 榮楷 陳; 匡華 季; 上惠(Sang H. Yen) 顏; 世薰(Su S. Lo) 羅; 銘芳 吳; 偉修(Wei S. Hwang) 黃; 嘉康(Jacqueline Whang-Peng) 彭汪; 敏(M. Liu) 劉; 光耀(Kuang Y. Chen) 陳

doi:10.6316/TRO/199401(3)263

A Pilot Study of Cisplatin, 5-Fluorouracil and High Dose Leucovorin in Chinese Patients with Head and Neck Cancer

林增熙, 陳榮楷, 季匡華, 顏上惠(Sang H. Yen), 羅世薰(Su S. Lo), 吳銘芳, 黃偉修(Wei S. Hwang), 彭汪嘉康(Jacqueline Whang-Peng), 劉敏(M. Liu), 陳光耀(Kuang Y. Chen)

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Cisplatin, 5-fluorouracil and high dose leucovorin PFL (HDLV) chemotherapy has been reported to be highly active in treatment of head and neck cancer patients. However overall toxicity was high. Before considering PFL (HDLV) chemotherapy for a phase III study in Taiwan, a pilot study of PFL (H DLV) chemotherapy is necessary.
Methods: Patients with histologically proven squamous cell carcinoma of head and neck, American Journal Committee on Cancer (AJCC) stage TV, previouly untreated, were eligible for study. Cisplatin 20mg/m^2, 5-fluorouracil (5-FU) 800mg/m^2, leucovorin (LV) 500mg/m^2 were given as a continuous intravenous infusion over 96 hours and the cycle repeated every 28 days. Patients were evaluated for the response and toxicity.
Results: Fourteen patients were studied. There were 1 CR (7%) and 8 PR (57%) with a overall response rate (CR+PR) of 64%. The major toxicities were mucositis and myelosuppression. Grade III to IV mucositis occurred in 35% of patients. No treatment related death occurred.
Conclusion: Although PFL (HDLV) is an active chemotherapy regiment in head and neck cancer, but its toxicity appears to be excessive. Other PFL regimens that may be equally active but much less toxic should be considered for further evaluation in future studies.

Translated title of the contribution	Cisplatin, 5Fluorouracil，高劑量Leucovorinl在中國人頭頸部癌病之前導性研究
Original language	English
Pages (from-to)	263-268
Number of pages	6
Journal	放射治療與腫瘤學
Volume	1
Issue number	3
DOIs	https://doi.org/10.6316/TRO/199401(3)263
Publication status	Published - 1994
Externally published	Yes

Keywords

Cisplatin
Leucovorin
5-FU
head and neck cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.6316/TRO/199401(3)263

Cite this

林增熙, 陳榮楷, 季匡華, 顏上惠(SangHY, 羅世薰(SuSL, 吳銘芳, 黃偉修(WeiSH, 彭汪嘉康(JacquelineW-P, 劉敏(ML & 陳光耀(KuangYC 1994, 'A Pilot Study of Cisplatin, 5-Fluorouracil and High Dose Leucovorin in Chinese Patients with Head and Neck Cancer', 放射治療與腫瘤學, vol. 1, no. 3, pp. 263-268. https://doi.org/10.6316/TRO/199401(3)263

@article{dba34a11e4564597a3e3c0a5d5fa2a8b,

title = "A Pilot Study of Cisplatin, 5-Fluorouracil and High Dose Leucovorin in Chinese Patients with Head and Neck Cancer",

abstract = "Background: Cisplatin, 5-fluorouracil and high dose leucovorin PFL (HDLV) chemotherapy has been reported to be highly active in treatment of head and neck cancer patients. However overall toxicity was high. Before considering PFL (HDLV) chemotherapy for a phase III study in Taiwan, a pilot study of PFL (H DLV) chemotherapy is necessary.Methods: Patients with histologically proven squamous cell carcinoma of head and neck, American Journal Committee on Cancer (AJCC) stage TV, previouly untreated, were eligible for study. Cisplatin 20mg/m^2, 5-fluorouracil (5-FU) 800mg/m^2, leucovorin (LV) 500mg/m^2 were given as a continuous intravenous infusion over 96 hours and the cycle repeated every 28 days. Patients were evaluated for the response and toxicity.Results: Fourteen patients were studied. There were 1 CR (7%) and 8 PR (57%) with a overall response rate (CR+PR) of 64%. The major toxicities were mucositis and myelosuppression. Grade III to IV mucositis occurred in 35% of patients. No treatment related death occurred.Conclusion: Although PFL (HDLV) is an active chemotherapy regiment in head and neck cancer, but its toxicity appears to be excessive. Other PFL regimens that may be equally active but much less toxic should be considered for further evaluation in future studies.",

keywords = "Cisplatin, Leucovorin, 5-FU, head and neck cancer, 頭頸癌治療, 5-FU, leucovorin, Cisplatin",

author = "增熙林 and 榮楷陳 and 匡華季 and 顏, {上惠(Sang H. Yen)} and 羅, {世薰(Su S. Lo)} and 銘芳吳 and 黃, {偉修(Wei S. Hwang)} and 彭汪, {嘉康(Jacqueline Whang-Peng)} and 劉, {敏(M. Liu)} and 陳, {光耀(Kuang Y. Chen)}",

year = "1994",

doi = "10.6316/TRO/199401(3)263",

language = "English",

volume = "1",

pages = "263--268",

journal = "放射治療與腫瘤學",

issn = "1023-988x",

publisher = "台灣放射腫瘤學會",

number = "3",

}

TY - JOUR

T1 - A Pilot Study of Cisplatin, 5-Fluorouracil and High Dose Leucovorin in Chinese Patients with Head and Neck Cancer

AU - 林, 增熙

AU - 陳, 榮楷

AU - 季, 匡華

AU - 顏, 上惠(Sang H. Yen)

AU - 羅, 世薰(Su S. Lo)

AU - 吳, 銘芳

AU - 黃, 偉修(Wei S. Hwang)

AU - 彭汪, 嘉康(Jacqueline Whang-Peng)

AU - 劉, 敏(M. Liu)

AU - 陳, 光耀(Kuang Y. Chen)

PY - 1994

Y1 - 1994

N2 - Background: Cisplatin, 5-fluorouracil and high dose leucovorin PFL (HDLV) chemotherapy has been reported to be highly active in treatment of head and neck cancer patients. However overall toxicity was high. Before considering PFL (HDLV) chemotherapy for a phase III study in Taiwan, a pilot study of PFL (H DLV) chemotherapy is necessary.Methods: Patients with histologically proven squamous cell carcinoma of head and neck, American Journal Committee on Cancer (AJCC) stage TV, previouly untreated, were eligible for study. Cisplatin 20mg/m^2, 5-fluorouracil (5-FU) 800mg/m^2, leucovorin (LV) 500mg/m^2 were given as a continuous intravenous infusion over 96 hours and the cycle repeated every 28 days. Patients were evaluated for the response and toxicity.Results: Fourteen patients were studied. There were 1 CR (7%) and 8 PR (57%) with a overall response rate (CR+PR) of 64%. The major toxicities were mucositis and myelosuppression. Grade III to IV mucositis occurred in 35% of patients. No treatment related death occurred.Conclusion: Although PFL (HDLV) is an active chemotherapy regiment in head and neck cancer, but its toxicity appears to be excessive. Other PFL regimens that may be equally active but much less toxic should be considered for further evaluation in future studies.

AB - Background: Cisplatin, 5-fluorouracil and high dose leucovorin PFL (HDLV) chemotherapy has been reported to be highly active in treatment of head and neck cancer patients. However overall toxicity was high. Before considering PFL (HDLV) chemotherapy for a phase III study in Taiwan, a pilot study of PFL (H DLV) chemotherapy is necessary.Methods: Patients with histologically proven squamous cell carcinoma of head and neck, American Journal Committee on Cancer (AJCC) stage TV, previouly untreated, were eligible for study. Cisplatin 20mg/m^2, 5-fluorouracil (5-FU) 800mg/m^2, leucovorin (LV) 500mg/m^2 were given as a continuous intravenous infusion over 96 hours and the cycle repeated every 28 days. Patients were evaluated for the response and toxicity.Results: Fourteen patients were studied. There were 1 CR (7%) and 8 PR (57%) with a overall response rate (CR+PR) of 64%. The major toxicities were mucositis and myelosuppression. Grade III to IV mucositis occurred in 35% of patients. No treatment related death occurred.Conclusion: Although PFL (HDLV) is an active chemotherapy regiment in head and neck cancer, but its toxicity appears to be excessive. Other PFL regimens that may be equally active but much less toxic should be considered for further evaluation in future studies.

KW - Cisplatin

KW - Leucovorin

KW - 5-FU

KW - head and neck cancer

KW - 頭頸癌治療

KW - 5-FU

KW - leucovorin

KW - Cisplatin

U2 - 10.6316/TRO/199401(3)263

DO - 10.6316/TRO/199401(3)263

M3 - Article

SN - 1023-988x

VL - 1

SP - 263

EP - 268

JO - 放射治療與腫瘤學

JF - 放射治療與腫瘤學

IS - 3

ER -

A Pilot Study of Cisplatin, 5-Fluorouracil and High Dose Leucovorin in Chinese Patients with Head and Neck Cancer

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this